GlassScriptPhysician profile
Meredith B Esner
NPI 1306148721
$2,225.95
in general payments reported to CMS, 2019-2025
25 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $422 · 2023: $470 · 2024: $394 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $407.39 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $270.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.85 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $181.99 | 2023-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $136.64 | 2021-2022 | |
| Novo Nordisk INC | $134.18 | 2023-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.36 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $96.05 | 2022-2025 | Amvuttra |
| Medtronic, INC. | $69.34 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $64.21 | 2021-2023 | Arcalyst |
| Boston Scientific Corporation | $59.34 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $57.18 | 2023-2025 | Opsumit |
| Edwards Lifesciences Corporation | $54.08 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Pfizer INC. | $53.69 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $53.26 | 2023-2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.99 | 2025 | Eliquis, Camzyos |
| Impulse Dynamics (USA) INC. | $32.58 | 2022 | |
| Daiichi Sankyo INC. | $28.53 | 2023 | Injectafer |
| Cardiva Medical, INC. | $27.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.31 | 2023 | |
| Abbott Laboratories | $22.02 | 2024 | Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $21.69 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $18.54 | 2023 | Assure Wcd |
| Chiesi USA, INC. | $16.23 | 2024 | Juxtapid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Esner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.